Elimination of the initiating event in leukemogenesis has proved to be an extremely effective therapeutic strategy, such as Gleevec for BCR‐ABL in chronical myeloid leukaemia51 and all‐trans retinoic acid for AML with PML‐RARα.52 These therapeutic strategies have produced tremendous advances in the treatment of AML patients. This evidence concerns the gene ABL1 and acute myeloid leukemia.